Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this non-inferiority study is to compare the safety and effectiveness of a
mineral and bone disease treatment protocol based on calcitriol to one based on paricalcitol
in hemodialysis patients using revised Kidney Disease: Improving Global Outcomes (KDIGO)
parathyroid hormone targets.